HBIO: Harvard Bioscience Inc. Price Target Chart

The laboratory equipment sector is characterized by fierce competition for government contracts and pressure from Eastern suppliers. Harvard Bioscience (HBIO) relies on consistent procurement from universities and pharmaceutical centers, which ensures a stable cash flow. The current figure is 10.22. Harvard Bioscience (HBIO) is scaling its product range by implementing automation for cell analysis. The historical price action is presented below and illustrates market sentiment toward the asset.

Harvard Bioscience, Inc. (HBIO): Price Target Chart from 07/04/2022 to 11/11/2026

Analytical breakdowns for Harvard Bioscience, Inc. (HBIO)

- share price and consensus valuation forecast:

Price Performance Chart harvardbioscience.com|HBIO - Analyst Consensus Forecast

- market capitalization information:

Market Value Harvard Bioscience|HBIO - Enterprise Value

- issuer book value statistics:

Net Assets per Share Harvard Bioscience|HBIO - Company Book Value|Market-to-Book Ratio harvardbioscience.com|HBIO - Aggregate Company Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

HBIO - Net Profit|Projected Future Earnings Harvard Bioscience|HBIO - Price to Earnings Ratio|Future Price to Earnings harvardbioscience.com|HBIO - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Harvard Bioscience|HBIO - Operating profit EBITDA|Net earnings per share for the last four quarters Harvard Bioscience|HBIO - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months harvardbioscience.com|HBIO - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Harvard Bioscience

General company analysis:harvardbioscience.com (HBIO)

Original product of Harvard Bioscience, Inc.

This indicator represents the weighted average fair value of the asset, calculated based on independent expert estimates to filter out market volatility. By analyzing the consensus target price forecast, an investor can see the aggregated potential of Harvard Bioscience (HBIO), which currently depends on the company's ability to scale sales of automated cell analysis systems amid stagnation in the academic segment.

Competing companies